14h
Hosted on MSNAnnexon Biosciences Reports Strong Progress in 2024Annexon Biosciences, Inc. ( ($ANNX) ) has released its Q4 earnings. Here is a breakdown of the information Annexon Biosciences, Inc. presented to ...
3d
TipRanks on MSNPacira BioSciences Reports Record Revenues and Strategic GrowthPacira (($PCRX)) has held its Q4 earnings call. Read on for the main highlights of the call. Pacira BioSciences’ recent earnings call painted a ...
Twist Bioscience Co. (NASDAQ:TWST) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Twist Bioscience Co. (NASDAQ:TWST – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the ten ratings firms that are covering the firm, Ratings reports. One investment ...
Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report)’s stock price gapped down before the market opened on Monday after Barclays lowered their price target on the stock from $63.00 to $57.00. The ...
Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates. Overall, the quarter showcased strong ...
We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished ...
Solid Biosciences reported recent positive data in developing their gene therapy candidate SGT-003. The phase 1/2 INSPIRE ...
Gorgas, President and CEO of Artelo Biosciences. “Notably, enrollment in our Phase 1 study of ART26.12, a Fatty Acid Binding Protein (FABP) inhibitor, has progressed rapidly and is expected to ...
Cytek will host a conference call to discuss its fourth quarter and year end 2024 financial results on Thursday, February 27, 2024, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A webcast of the ...
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-reports-fourth-quarter-and-fiscal-2024-financial-results ...
the estimate revisions trend for Twist Bioscience: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current ...
Before you invest in Twist Bioscience Corporation (TWST), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results